Binghe Xu

28.3k total citations · 7 hit papers
387 papers, 9.1k citations indexed

About

Binghe Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Binghe Xu has authored 387 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 303 papers in Oncology, 195 papers in Pulmonary and Respiratory Medicine and 133 papers in Cancer Research. Recurrent topics in Binghe Xu's work include Advanced Breast Cancer Therapies (144 papers), HER2/EGFR in Cancer Research (141 papers) and Cancer Treatment and Pharmacology (102 papers). Binghe Xu is often cited by papers focused on Advanced Breast Cancer Therapies (144 papers), HER2/EGFR in Cancer Research (141 papers) and Cancer Treatment and Pharmacology (102 papers). Binghe Xu collaborates with scholars based in China, United States and South Korea. Binghe Xu's co-authors include Seock‐Ah Im, Norikazu Masuda, Fei Ma, Mark E. Robson, Pierfranco Conté, Elżbieta Senkus, Anne Armstrong, Nadine Tung, Susan M. Domchek and Suzette Delaloge and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Communications.

In The Last Decade

Binghe Xu

364 papers receiving 9.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine profile →
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 497 citations Mark E. Robson, Nadine Tung et al. profile →
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

2021 434 citations Hongnan Mo, Xiaoying Sun et al. profile →
Breast cancer: an up‐to‐date review and future perspectives

2022 206 citations Binghe Xu et al. Cancer Communications profile →
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial

2024 45 citations Qiao Li, Quchang Ouyang et al. profile →
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer

2025 25 citations Hongnan Mo, Xiaoying Sun et al. profile →
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

2025 16 citations Yongmei Yin, Ying Fan et al. Nature Medicine profile →

Peers

Countries citing papers authored by Binghe Xu

Since Specialization

Citations

This map shows the geographic impact of Binghe Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Binghe Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Binghe Xu more than expected).

Fields of papers citing papers by Binghe Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Binghe Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Binghe Xu. The network helps show where Binghe Xu may publish in the future.

Co-authorship network of co-authors of Binghe Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Binghe Xu. A scholar is included among the top collaborators of Binghe Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Binghe Xu. Binghe Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial breakdown → 2025 ·Nature Medicine ·Yongmei Yin, Ying Fan, (unknown), (unknown), Xiaojia Wang, Wěi Li, Man Li, Xi Yan, Shusen Wang, Tao Sun, (unknown), (unknown), Zhongsheng Tong, (unknown), (unknown), Xiaoping Jin, (unknown), (unknown), Binghe Xu	16
2	PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma 2025 ·Cell Death and Disease ·Chen‐Hong Ding, (unknown), Binghe Xu, Hui Qian, (unknown), Shuqing Liu, Yuanyuan Luo, Sihan Wu, (unknown), Xin Zhang, Wei‐Fen Xie	11
3	Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial. 2024 ·Journal of Clinical Oncology ·Jiani Wang, Qingyuan Zhang, Xichun Hu, Qing Li, Tao Sun, Wěi Li, Quchang Ouyang, Jingfen Wang, Zhongsheng Tong, Min Yan, Huiping Li, Xiaohua Zeng, (unknown), Xian Wang, Jian Zhang, (unknown), Liang Zhang, Ying Tian, Hongyan Shang, Binghe Xu	0
4	Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. 2024 ·Journal of Clinical Oncology ·Sònia Pernas, Seock‐Ah Im, Masaya Hattori, Binghe Xu, Shusen Wang, Yen‐Shen Lu, Giuliano Borges, Junji Tsurutani, Komal Jhaveri, Qingyuan Zhang, Michelino De Laurentiis, Noelia Martínez-Jáñez, Erika Hamilton, Hope S. Rugo, Kevin Kalinsky, Sara M. Tolaney, Lei Shi, (unknown), (unknown), Aditya Bardia	1
5	International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor. 2024 ·Journal of Clinical Oncology ·(unknown), Michail Ignatiadis, Carlos H. Barrios, François‐Clément Bidard, Binghe Xu, (unknown), Jason Gong, (unknown), Prashanth Gopalakrishna, Hope S. Rugo	2
6	Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients 2024 ·BMC Cancer ·Yan Wang, (unknown), (unknown), Li Li, Yiqun Han, Yun Wu, Yiran Zhou, Binghe Xu, Jiayu Wang	1
7	Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial 2024 ·Nature Medicine ·Hongnan Mo, Yongpei Yu, Xiaoying Sun, (unknown), (unknown), Xiuwen Guan, Jingtong Zhai, Aihua Zhu, (unknown), Jinjing Wang, Xiaoyan Yan, Haili Qian, Binghe Xu, Fei Ma	11
8	Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer 2023 ·Cancer Biology and Medicine ·(unknown), Xue Wang, Feng Du, Jian Yue, Yiran Si, Xiaochen Zhao, Lina Cui, Bei Zhang, Ting Bei, Binghe Xu, Peng Yuan	7
9	Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution 2023 ·BMC Geriatrics ·Huiyao Huang, Yu Tang, Dawei Wu, (unknown), Shuhang Wang, Jun Wang, (unknown), (unknown), Hong Fang, Qi Zhu, Ning Li, Binghe Xu, (unknown), Jie He	4
10	Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study) 2023 ·European Journal of Cancer ·Jiayu Wang, Li Cai, Yanqiu Song, Tong Sun, Zhongsheng Tong, Yuee Teng, Huiping Li, Quchang Ouyang, Qianjun Chen, Shude Cui, Yongmei Yin, Ning Liao, Qiang Sun, Jifeng Feng, Xiaojia Wang, Binghe Xu	7
11	Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer 2023 ·Journal of Personalized Medicine ·Yiqun Han, Jiayu Wang, Binghe Xu	5
12	Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China 2020 ·Cancer Communications ·Zongbi Yi, Fei Ma, Guohua Rong, Yanfang Guan, Chunxiao Li, Binghe Xu	17
13	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial 2019 ·Clinical Cancer Research ·Qiao Li, Xiuwen Guan, Shanshan Chen, Zongbi Yi, Bo Lan, Puyuan Xing, Ying Fan, Jiayu Wang, Yang Luo, Peng Yuan, Ruigang Cai, Pin Zhang, Qing Li, Dafang Zhong, Yifan Zhang, (unknown), Xiaoyu Zhu, Fei Ma, Binghe Xu	61
14	Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes 2019 ·Cancer Medicine ·Jiayu Wang, (unknown), Yujian Shi, (unknown), Tao Sun, Lili Tang, Qing Lü, (unknown), Ning Liao, Feng Jin, (unknown), Tao Huang, Jun Qian, Danmei Pang, Shusen Wang, (unknown), Xinhong Wu, Ying Lin, Haiyan Qin, Binghe Xu	17
15	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma 2018 ·Clinical Cancer Research ·Jing Huang, Binghe Xu, Hongnan Mo, (unknown), Xuelian Chen, Dawei Wu, Dong Qu, Xingyuan Wang, Bo Lan, Beibei Yang, Pei Wang, Hong‐Tu Zhang, Qing Yang, Yuchen Jiao	149
16	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation breakdown → 2017 ·New England Journal of Medicine ·Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wěi Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, Pierfranco Conté	2156
17	[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]. 2012 ·PubMed ·(unknown), Pin Zhang, Bailin Zhang, Xiang Wang, (unknown), Shan Zheng, Jiayu Wang, Ruigang Cai, Peng Yuan, Fei Ma, (unknown), Binghe Xu	3
18	Genome-Wide Interrogation Identifies YAP1 Variants Associated with Survival of Small-Cell Lung Cancer Patients 2010 ·Cancer Research ·Chen Wu, Binghe Xu, Peng Yuan, Xiaoping Miao, Yu Liu, (unknown), Dianke Yu, Jian Xu, Tongwen Zhang, Hongbing Shen, Tangchun Wu, Dongxin Lin	42
19	Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis 2008 ·Clinical Cancer Research ·Dianke Yu, Xuemei Zhang, Ju Liu, Peng Yuan, Wen Tan, Yongli Guo, Tong Sun, Dan Zhao, Ming Yang, (unknown), Binghe Xu, Dongxin Lin	44
20	[Clinical characteristics and prognosis of breast cancer patients with vascular invasion]. 2007 ·PubMed ·(unknown), Binghe Xu, Pin Zhang, Qing Li, (unknown), Yan Sun	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact